Monamine oxidase inhibitors: Current and emerging agents for Parkinson disease

被引:48
作者
Fernandez, Hubert H. [1 ]
Chen, Jack J.
机构
[1] Univ Florida, McKnight Brain Inst, Dept Neurol, Movement Disorders Ctr, Gainesville, FL 32610 USA
[2] Loma Linda Univ, Sch Pharm, Loma Linda, CA 92350 USA
关键词
Parkinson disease; MAO-B inhibitor; rasagiline; selegiline; Zydis selegiline;
D O I
10.1097/01.WNF.0000240956.49315.BE
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Monoamine oxidase type B (MAO-B) is the predominant isoform responsible for the metabolic breakdown of dopamine in the brain. Selective inhibition of brain MAO-13 results in elevation of synaptosomal dopamine concentrations. Data have been reported regarding the selective MAO-B inhibitors, rasagiline and selegiline, for the symptomatic treatment of Parkinson disease (PD). Selegiline has demonstrated efficacy as monotherapy in patients with early PD (Deprenyl and Tocopherol Antioxidative Therapy of Parkinsonism study), but evidence of selegiline efficacy as adjunctive treatment in levodopa-treated PD patients with motor fluctuations is equivocal. A new formulation of selegiline (Zydis selegiline) has been evaluated in 2 small, placebo-controlled studies as adjunctive therapy to levodopa. The Zydis formulation allows pregastric absorption of selegiline, minimizing first-pass metabolism, and thereby increasing selegillne bioavailability and reducing the concentration of amphetamine metabolites. Rasagiline is a selective, second-generation, irreversible MAO-B inhibitor, with at least 5 times the potency of selegiline in vitro and in animal models. Rasagiline has demon strated efficacy in I large, randomized, doubleblind, placebo-controlled trial (TVP-1012 in Early Monotherapy for Parkinson's Disease Outpatients) as initial monotherapy in patients with early PD, and in 2 large, controlled trials (Parkinson's Rasagiline: Efficacy and Safety in the Treatment of "Off," Lasting Effect in Adjunct Therapy With Rasagiline Given Once Daily) as adjunctive treatment in levodopa-treated PD patients with motor fluctuations. Unlike selegiline, rasagiline is an aminoindan derivative with no amphetamine metabolites. A randomized clinical trial is underway to confirm preclinical and preliminary clinical data suggesting rasagiline has disease-modifying effects.
引用
收藏
页码:150 / 168
页数:19
相关论文
共 98 条
[1]   Neuroprotective and neurotoxic effects of monoamine oxidase-B inhibitors and derived metabolites under ischemia in PC12 cells [J].
Abu-Raya, S ;
Tabakman, R ;
Blaugrund, E ;
Trembovler, V ;
Lazarovici, P .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2002, 434 (03) :109-116
[2]   Mitochondrial permeability transition mediates apoptosis induced by N-methyl(R)salsolinol, an endogenous neurotoxin, and is inhibited by Bcl-2 and rasagiline, N-propargyl-1(R)-aminoindan [J].
Akao, Y ;
Maruyama, W ;
Shimizu, S ;
Yi, H ;
Nakagawa, Y ;
Shamoto-Nagai, M ;
Youdim, MBH ;
Tsujimoto, Y ;
Naoi, M .
JOURNAL OF NEUROCHEMISTRY, 2002, 82 (04) :913-923
[3]  
[Anonymous], 1996, Ann Neurol, V39, P29
[4]  
[Anonymous], 1996, Ann Neurol, V39, P37
[5]   Contrasting neuroprotective and neurotoxic actions of respective metabolites of anti-Parkinson drugs rasagiline and selegiline [J].
Bar Am, O ;
Amit, T ;
Youdim, MBH .
NEUROSCIENCE LETTERS, 2004, 355 (03) :169-172
[6]   Rasagiline improves quality of life in patients with early Parkinson's disease [J].
Biglan, KM ;
Schwid, S ;
Eberly, S ;
Blindauer, K ;
Fahn, S ;
Goren, T ;
Kieburtz, K ;
Oakes, D ;
Plumb, S ;
Siderowf, A ;
Stern, M ;
Shoulson, I .
MOVEMENT DISORDERS, 2006, 21 (05) :616-623
[7]   Neuroprotective effect of rasagiline in a rodent model of Parkinson's disease [J].
Blandini, F ;
Armentero, MT ;
Fancellu, R ;
Blaugrund, E ;
Nappi, G .
EXPERIMENTAL NEUROLOGY, 2004, 187 (02) :455-459
[8]  
Blindauer K, 2001, NEUROLOGY, V56, pA345
[9]   Clinical pharmacology of rasagiline: A novel, second-generation propargylamine for the treatment of Parkinson disease [J].
Chen, JJ ;
Swope, DM .
JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 45 (08) :878-894
[10]   Synaptic uptake and beyond: the sodium- and chloride-dependent neurotransmitter transporter family SLC6 [J].
Chen, NH ;
Reith, MEA ;
Quick, MW .
PFLUGERS ARCHIV-EUROPEAN JOURNAL OF PHYSIOLOGY, 2004, 447 (05) :519-531